Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 3,269,753 shares, an increase of 26.5% from the August 15th total of 2,584,873 shares. Based on an average trading volume of 223,163 shares, the days-to-cover ratio is currently 14.7 days. Currently, 11.5% of the company’s shares are short sold.
Separately, Zacks Investment Research downgraded Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 25th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $13.21.
Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 2.65 on Friday. The stock’s 50 day moving average price is $1.69 and its 200 day moving average price is $2.30. Aegerion Pharmaceuticals has a one year low of $1.23 and a one year high of $16.97. The company’s market capitalization is $78.21 million.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.34. Aegerion Pharmaceuticals had a negative net margin of 80.76% and a negative return on equity of 128.77%. The business had revenue of $44.50 million for the quarter, compared to analysts’ expectations of $35.50 million. Equities analysts anticipate that Aegerion Pharmaceuticals will post ($3.44) EPS for the current fiscal year.
In other Aegerion Pharmaceuticals news, major shareholder Healthcare Master Fun Broadfin bought 276,000 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The stock was bought at an average price of $1.66 per share, for a total transaction of $458,160.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Artal Group S.A. acquired a new position in Aegerion Pharmaceuticals during the second quarter worth about $1,490,000. Eqis Capital Management Inc. boosted its position in Aegerion Pharmaceuticals by 3.9% in the second quarter. Eqis Capital Management Inc. now owns 87,458 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 3,255 shares during the last quarter. Squarepoint Ops LLC boosted its position in Aegerion Pharmaceuticals by 9.1% in the first quarter. Squarepoint Ops LLC now owns 34,906 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 2,906 shares during the last quarter. Royal Bank of Canada boosted its position in Aegerion Pharmaceuticals by 1,193.5% in the first quarter. Royal Bank of Canada now owns 58,247 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 53,744 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Aegerion Pharmaceuticals during the first quarter worth about $574,000. Institutional investors own 87.60% of the company’s stock.
Aegerion Pharmaceuticals Company Profile
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.